IL2-receptor antagonist (basiliximab) induction therapy is associated with lower morbidity and mortality in renal transplant recipients.
Choy
B Y
BY
Division of Nephrology, Department of Medicine, Queen Mary Hospital, Hong Kong, China. choybyc@hku.hk
Chan
T M
TM
Li
F K
FK
Lui
S L
SL
Lo
W K
WK
Yip
T
T
Tse
K C
KC
Lai
K N
KN
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000077552:Basiliximab; D004359:Drug Therapy, Combination; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000009:adverse effects / Q000276:immunology*; D008297:Male; D009017:Morbidity; D011183:Postoperative Complications / Q000145:classification / Q000453:epidemiology / Q000517:prevention & control; D011993:Recombinant Fusion Proteins; D012189:Retrospective Studies
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab